The global diabetes and obesity epidemic is driving another expansion of Novo Nordisk’s drug-manufacturing operations at its 264-acre campus in Clayton. The company will begin a $65 million expansion ...

However, none of the low-carbohydrate meal plans could meet all of the calorie and nutrient needs of each studied gender and age group. The study received funding from Simply Good Foods USA ...

DSV A/S’s new acquisition, the $15.9 billion takeover of DB Schenker, will almost double the freight company’s sales, making it Denmark’s second-largest firm by that measure and pushing Novo ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, and congratulations on making it through another week.

Gift 5 articles to anyone you choose each month when you subscribe. Ozempic maker Novo Nordisk says its highly anticipated experimental weight-loss pill Amycretin was safe and tolerable for ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

Eli Lilly and Novo Nordisk have been top stocks for investors who are bullish on the weight loss market. However, fellow biotech Amgen could possess more upside given its more modest valuation.

Rakul Preet Singh Shares Her Top Protein-rich Foods For Vegetarians; Here's Why They Are A Must For Your Diet Plan ...

Share on Pinterest Novo Nordisk is testing a new pill for weight loss that could be more effective than injectable GLP-1 drugs like Ozempic and Wegovy. Christian Schultz/picture alliance via Getty ...

No­vo Nordisk tout­ed more da­ta for its oral amy­cretin, not­ing that sub­jects had not reached a plateau in their weight loss at the end of … ...

Ozempic maker Novo Nordisk on Wednesday said data showed its hotly anticipated weight loss pill prompts greater and more rapid weight loss than its blockbuster treatment Wegovy, amid competition ...